Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Archer Materials ( (AU:AXE) ) has shared an announcement.
Archer Materials reported 1H FY26 progress marked by a major technical breakthrough in its carbon-based quantum computing program, achieving on-chip electrical readout of quantum states via EDMR and SET devices and validating CMOS-compatible, wafer-scale manufacturing. The company advanced its 12CQ project with cryogenic TMR sensor performance, strengthened partnerships with Emergence Quantum and CSIRO, and remains on track for targeted qubit demonstration in 2026.
In medical diagnostics, Archer enhanced its Biochip strategy through a dual graphene and silicon platform, completing an initial silicon-based blood potassium sensor project with IMEC and demonstrating clinically aligned accuracy in human blood tests. The company is targeting a functional Biochip prototype in 2026 for point-of-care chronic kidney disease testing, supported by a strong cash position of $10.3 million and an expanded board to accelerate R&D and commercialisation.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.36 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.
More about Archer Materials
Archer Materials Limited is an Australian quantum technology company developing hardware and devices for computing, sensing, and medical diagnostics. Its core programs span carbon-based qubits for quantum computing, tunnel magnetoresistance sensors for advanced magnetic field detection, and a Biochip platform aimed at point-of-care blood testing, with a particular focus on chronic kidney disease management.
Average Trading Volume: 249,141
Technical Sentiment Signal: Hold
Current Market Cap: A$94.29M
See more data about AXE stock on TipRanks’ Stock Analysis page.